| 42nd week of 2010 patent applcation highlights part 35 |
| Patent application number | Title | Published |
|---|
| 20100266500 | STILBENE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES - This invention relates to a method of imaging amyloid deposits and to labeled compounds, and methods of making labeled compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits. | 2010-10-21 |
| 20100266501 | METHODS AND COMPOSITIONS FOR ORGAN PROTECTION - The invention relates in some aspects to compositions that include a contrast agent and an antioxidant compound and the use of such compositions to prevent (e.g., reduce) organ damage in a subject. In some aspects, the invention relates to compositions that include N— acetylcysteine (NAC) and a contrast agent and the use of such compositions for preventing organ damage in a subject. Methods of preventing organ damage may include the simultaneous administration of a composition of the invention, such that a contrast agent and an antioxidant compound or a contrast agent and NAC are administered intravascularly to a subject. Examples of organ damage that may be treated with compositions and methods of the invention include contrast-induced and non-contrast induced organ damage associated with myocardial ischemia, myocardial infarction, reperfusion damage, nephropathy, etc. The invention, in some aspects, also includes kits that may include a contrast agent and NAC and/or an antioxidant compound. | 2010-10-21 |
| 20100266502 | Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient - An anti-HB-EGF antibody having an internalizing activity is disclosed. A cytotoxic substance is preferably bound to the anti-HB-EGF antibody of the present invention. Also provided are an anti-cancer agent and a cell proliferation inhibitor, which comprise the antibody of the present invention as an active ingredient, a method of treating cancer and a method of diagnosing cancer, which comprise the administration of the antibody of the present invention. Cancers that can be treated by the anti-cancer agent of the present invention include pancreatic cancer, liver cancer, esophageal cancer, melanoma, colorectal cancer, gastric cancer, ovarian cancer, uterine cervical cancer, breast cancer, bladder cancer, brain tumors, and hematological cancers. | 2010-10-21 |
| 20100266503 | Breast Cancer Methods, Medicaments and Agents - A method of combating breast cancer in a mammalian individual, the method comprising administering to the individual an agent which reduces the function of the gamma secretase (GS) complex. | 2010-10-21 |
| 20100266504 | CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF - Provided are a condensed pyridine derivative having a serotonin 5-HT | 2010-10-21 |
| 20100266505 | IMMUNOTHERAPY REGIMES DEPENDENT ON APOE STATUS - The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered to a patient depends on the ApoE genotype of the patient. | 2010-10-21 |
| 20100266506 | Flourescent Dendrimer Compounds and Use of Such Compounds in Multi-Photon Devices or Processes - Fluorescent chemical compound composed of an n-generation dendrimer, n being a non-zero integer, exhibiting: -at least one central nucleus (N) with a valency of m, selected from the group consisting of -at least one first, non-chromophoric unit (X) with a valency of m′, and -at least one second unit (Y) which exhibits two-photon absorption properties, with a valency of m″. | 2010-10-21 |
| 20100266507 | LUMINESCENT COMPOUNDS - Luminescent reporter compounds that are rotaxanes having the structure | 2010-10-21 |
| 20100266508 | STABILIZED GOLD NANOPARTICLE AND CONTRAST AGENT - A kit for providing a contrast enhancer in a mammal for contrasting during imaging of the mammal comprises functionalized gold nanoparticles configured to be directed to one or more of a target organ, tissue and lesion of the mammal. | 2010-10-21 |
| 20100266509 | HETEROARYL AMIDE ANALOGUES AS P2X7 ANTAGONISTS - Heteroaryl amide analogues are provided, of Formula (I), wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands for receptor localization studies. | 2010-10-21 |
| 20100266510 | Foamable Vehicle and Pharmaceutical Compositions Thereof - A hygroscopic pharmaceutical composition includes at least one hygroscopic substance at a concentration sufficient to provide an Aw value of at least 0.9 and an antiinfective agent. A foamble pharmaceutical carrier includes about 50% to about 98% of a polar solvent selected from the group consisting of a polyol and PEG; 0% to about 48% of a secondary polar solvent; about 0.2% to about 5% by weight of a surface-active agent; about 0.01% to about 5% by weight of at least one polymeric agent; and a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition. | 2010-10-21 |
| 20100266511 | PHARMACEUTICAL FOAM - The present invention provides various pharmaceutically active topical delivery compositions. In particular, compositions of the present invention are present in a pressurized container comprising a quick-breaking alcoholic foaming agent, such that when the composition is released, i.e., dispensed, from the pressurized container, a quick-breaking temperature sensitive foam is formed. In addition, the present invention provides various aspects related to such compositions, including methods for modulating a foam characteristic, methods for improving the shelf-life of a pharmaceutically active compound, methods for the percutaneous treatment of various diseases, infections, and illnesses, and methods for evaluating foam characteristics. | 2010-10-21 |
| 20100266512 | CROSSLINKED HYALURONIC ACID IN EMULSION - The present invention relates to methods of producing crosslinked hyaluronic acid microbeads, as well as the produced microbeads, said method comprising the steps of: (a) providing an aqueous alkaline solution comprising hyaluronic acid, or a salt thereof; (b) forming microdroplets having a desired size from the mixed solution of step (a) in an organic or oil phase to form a water in organic or water in oil (VWO) emulsion, wherein the amount of oil phase used is of from 20 to less than 50% by weight based on the sum of oil phase and water; (c) adding a solution comprising a crosslinking agent to the emulsion, whereby the reaction of hyaluronic acid with the crosslinking agent takes place to provide crosslinked hyaluronic acid microbeads; and (d) optionally working up the dispersion of crosslinked hyaluronic acid microbeads obtained in step (c). | 2010-10-21 |
| 20100266513 | AMPHIPHILIC POLYMERIC MATERIAL - The present invention concerns an amphiphilic polymeric material which comprises a straight or branched chain carbon-carbon backbone and a multiplicity of side chains attached to the backbone, wherein the side chains have formula (I). At least one of R | 2010-10-21 |
| 20100266514 | Dual Component Dental Composition Containing Enzyme - A two component desensitizing dentifrice composition is disclosed which comprises a first dentifrice component containing an enzyme such as papain and a second dentifrice component containing an ionic surfactant such as sodium lauryl sulfate, the first and second dentifrice components being maintained separate from the other until dispensed for application to teeth whereby enzyme activity is maintained with improved dentifrice foaming characteristics. | 2010-10-21 |
| 20100266515 | TREATMENT OF MALODOUR - This invention relates to methods for inhibiting growth of anaerobic bacteria, particularly halitosis causing bacteria. The methods use BLIS-producing | 2010-10-21 |
| 20100266516 | PERSONAL CARE COMPOSITION - An aqueous shear-thinning personal care composition comprises: (a) at least 3 wt % of a sulfonate compound of general formula (I): where R | 2010-10-21 |
| 20100266517 | Two-Coat Cosmetic Compositions - Two-coat compositions and methods are provided for forming cosmetic films on a biological surface which are long-lasting, transfer-resistant, water-proof, oil-proof, non-migrating, comfortable to wear, and which are capable of filling in fine lines and wrinkles. The two-coat compositions generally comprise a hydrophilic base coat composition and a top coat composition, and are useful for formulating cosmetics and personal care products. | 2010-10-21 |
| 20100266518 | Process for the preparation of odourless polyether alcohols using DMC catalysts and their use in cosmetic and/or dermatological preparations - Cosmetic and/or dermatological preparations prepared using polyether alcohols, characterized in that, for the preparation of the polyether alcohol,
| 2010-10-21 |
| 20100266519 | Production Method Of A Powder Cosmetic - The present invention is to provide an easy production method of powder cosmetics having improved practical characteristics such as extensibility on the skin, adhesion, feeling of particulate fineness, and long-lasting property, and having improved impact resistance. A production method of a powder cosmetic comprising; mixing powder component and oil component as a binder with a mixing apparatus, wherein the mixing apparatus is a facing rotor type mixing apparatus having a first rotor with a plurality of blades and a second rotor with a plurality of blades in a mixing chamber, in which the first rotor and the second rotor face each other and have rotating shafts on same axis line, and in the facing rotor type mixing apparatus, raw materials are fed into an introduction opening on a first rotor side, the raw materials are mixed by rotating the first rotor and the second rotor in same or opposite directions to each other, and the mixed raw materials are discharged from a discharge opening on a second rotor side. | 2010-10-21 |
| 20100266520 | COSMETIC COMPOSITION COMPRISING A SEMICRYSTALLINE POLYURETHANE/POLYESTER COPOLYMER - The present invention relates to a cosmetic composition including, in a physiologically acceptable medium, an effective quantity of at least one semicrystalline polyurethane/polyester copolymer and at least one dye substance, the copolymer having a melting point greater than or equal to 20° C. | 2010-10-21 |
| 20100266521 | Stabilized Cationic Ammonium Compounds and Compositions Comprising the Same - Stabilized cationic ammonium compounds are described. The compounds are stabilized with metal chelators that impede the generation of nitrogen comprising groups from the cationic ammonium compounds. | 2010-10-21 |
| 20100266522 | Petrolatum Based Composition Comprising Greater Than 10% Silicone for Improved Feel While Remaining Stable - The present invention discloses petrolatum based composition containing silicone oils which are structured with specific blend and ratio of fatty acids. | 2010-10-21 |
| 20100266523 | COMPOSITIONS CONTAINING FLAVANOID POLYPHENOL DERIVATIVES, AND APPLICATIONS THEREOF IN CONTROLLING DISEASES AND AGEING OF LIVING ORGANISMS - The invention relates to compositions of polyphenol derivatives, characterised in that said polyphenols contain monomers, oligomers or polymers of units of the formula (I), wherein said units are characterised by the simultaneous presence of a phloroglucinol-type core (core A) and of a catechol-type core (core B) bonded together by a segment of 3 carbons such as C, said derivatives being over-activated in terms of nucleophilic power by the alkylation of at least one phenol function of each constituent monomer unit, and stabilised by the esterification of all the others with mixtures of fatty acids in proportions representing those of vegetable oils mainly consisting of AGI. These compositions can particularly be used in cosmetics, nutrition and therapy. | 2010-10-21 |
| 20100266524 | Composition Comprising Silicone Oil or Oils Structured With Compolymers Carrying Greater Than 70% Long Chain Alkyl Group - The present invention discloses silicone oils which are structured with a copolymer comprising a large percentage of alkane groups. Using high percentage pendant alkane helps provide silicone with ideal gel properties (G′>G″, particularly >1000 cP, more preferably 2000-30,000 cP) and viscosity, after fracture, of 10 to 1000 cP, preferably 30-500 cP MW of polymer and exact chain length are selected to ensure that, when forming gel upon cooling after mixing polymer and silicone, the polymer viscosity will not be so high upon crystal formation that gel cannot form, yet also will not be so low that polymer will phase separate. | 2010-10-21 |
| 20100266525 | METHOD FOR REMOVING MICROBES FROM SURFACES - A method has been found for the removal of microbial biofilm on surfaces in contact with systems, including but not limited to aqueous systems, which comprises adding to the aqueous system an effective amount of a carbosilane-based surfactant to substantially remove microbial biofilm, from surfaces in aquatic systems, while presenting minimal danger to non-target aquatic organisms at discharge due to their very low discharge concentrations. | 2010-10-21 |
| 20100266526 | Combination therapy for treating hypercholesterolemia - The invention relates to methods for treating hypercholesterolemia and atherosclerosis, and reducing serum cholesterol in a mammal. The methods of the invention comprise administering to a mammal a first amount of a bile acid sequestrant compound which is an unsubstituted polydiallylamine polymer and a second amount of a cholesterol-lowering agent. The first and second amounts together comprise a therapeutically effective amount. | 2010-10-21 |
| 20100266527 | ANTI-MICROBIAL POLYMERS AND THEIR COMPOSITIONS - Polymers derived directly from acrolein monomer that are substantially soluble in water and/or aqueous media, together with methods for preparing same and compositions containing such for use as an anti-microbial, anti-cancer, anti-inflammatory and/or anti-coagulant. | 2010-10-21 |
| 20100266528 | Systemic Administration of Colony Stimulating Factors to Treat Amyloid Associated Disorders - The invention relates a method of treating amyloidosis, diseases and disorders associated with amyloid plaque formation, e.g., Alzheimer's disease by increasing tissue resident macrophage activity in an organ or tissue of an animal requiring treatment by systemic administration of a colony stimulating factor. For example, the activity of bone marrow-derived microglial cells in an organ or tissue can be increased by systemic administration of a colony stimulating factor, particularly macrophage colony stimulating factor, either alone or in combination with additional colony stimulating factors, stem cell factors or other compounds capable of treating amyloidosis. | 2010-10-21 |
| 20100266529 | Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof - The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in the proteins using site-directed mutagenesis and then covalently coupling a cysteine-reactive polymer or other type of cysteine-reactive moiety to the proteins via the added cysteine residue. Disclosed herein are preferred sites for adding cysteine residues or introducing cysteine substitutions into the proteins, and the proteins and protein derivatives produced thereby. Also disclosed are therapeutic methods for using the cysteine variants of the invention. | 2010-10-21 |
| 20100266530 | FcRN ANTIBODIES AND USES THEREOF - In certain embodiments, this present invention provides polypeptide compositions (e.g., antibodies and antigen binding portions thereof that bind to FcRn), and methods for modulating FcRn activity. In other embodiments, the present invention provides methods and compositions for treating autoimmune disorders. | 2010-10-21 |
| 20100266531 | IL-17 BINDING PROTEINS - Proteins that bind IL-17 and/or IL-17F are described along with there use in composition and methods for treating, preventing, and diagnosing IL-17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions. | 2010-10-21 |
| 20100266532 | METHODS FOR INHIBITING SCARRING - The invention provides new methods of treatment using anti-scarring agents to inhibit scarring in humans, and also provides anti-scarring agents for new uses in the inhibition of scarring in humans. In a first incidence of treatment an anti-scarring agent is provided to each centimetre of a wound margin or each centimetre of a site at which a wound is to be formed in a first therapeutically effective amount; and in a subsequent incidence of treatment the anti-scarring agent is provided to each centimetre of wound margin in a larger therapeutically effective amount. The incidences of treatment occur between 8 hours and 48 hours apart from one another. The anti-scarring agent is preferably not TGF-β3. The anti-scarring agent may be provided by intradermal N injection. Also provided are kits and methods of selecting an appropriate treatment regime for inhibiting scarring associated with the healing of a human wound. | 2010-10-21 |
| 20100266533 | Death Domain Containing Receptors - The present invention relates to novel Death Domain Containing Receptor (DR3 and DR3-V1) proteins that are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR3 and DR3-V1 proteins. DR3 and DR3-V1 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. Also provided are antibodies and fragments thereof that bind to polypeptides of the invention. The invention further relates to screening methods for identifying agonists and antagonists of DR3 and DR3-V1 activity. | 2010-10-21 |
| 20100266534 | Human Lymphocyte Vaccine Adjuvant - The present invention relates to an adjuvant derived from human lymphocytes. The adjuvant can be used in combination with traditional vaccines or cancer immunotherapy, to enhance the response of the patient's immune system to the vaccine or other immunotherapeutic agent. The adjuvant is derived from the supernatant collected from cultured activated lymphocytes. | 2010-10-21 |
| 20100266535 | Compounds Having CRTH2 Antagonist Activity - Compounds of general formula (II) | 2010-10-21 |
| 20100266536 | NEW TYPE OF CONSENSUS INTERFERON AND PREPARATION METHOD THEREOF - The invention relates to variants of consensus interferon protein with improved properties, such as improved anti-viral activity, and use thereof. The variants are also easier to renature after denaturant treatment. The invention also relates to the preparation method of the variants consensus interferon. | 2010-10-21 |
| 20100266537 | HCV INHIBITORS - The present invention is directed to compounds that are antiviral agents. Specifically the compounds of the present invention inhibit replication of HCV and are therefore useful in treating hepatitis C infections. The present invention is also directed to pharmaceutical compositions comprising these compounds and processes for preparing them. | 2010-10-21 |
| 20100266538 | QUINOXALINE DERIVATIVES AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOUR DISORDERS - The invention provides quinoxalines of the general formula I which are used as medicaments preferably for treating tumour disorders, in particular in cases of drug resistance to other active compounds and in cases of metastasic carcinoma. The possible applications are not limited to tumour disorders. | 2010-10-21 |
| 20100266539 | CHEMOKINE RECEPTOR ANTAGONIST AND MEDICAL USE THEREOF - The present invention relates to a compound represented by formula (I), a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof, and medical use thereof (the symbols in the formula are as described in the specification). | 2010-10-21 |
| 20100266540 | DRUG CLASS FOR THE TREATMENT OF CANCER - Compositions, methods, and combination therapies for the treatment of cancers, including lymphomas, leukemias, melanomas, lung cancer, and metastatic disease, are provided. Specifically, compositions comprising ligands to Pgrmc1 are disclosed for use in treating and inhibiting tumor growth and progression and inhibition of metastases. The compositions and methods using these ligands can be used alone or in combination with other reagents and cancer treatment modalities. | 2010-10-21 |
| 20100266541 | METHODS AND AGENTS FOR MODULATING AN IMMUNE RESPONSE - This invention is directed to the targeting of proteins or peptides of interest to an autophagosome, for their presentation on a major histocompatibility complex (MHC) class II molecule and methods of use thereof. Nucleic acids, vectors comprising the same, and compositions for targeting proteins or peptides of interest to an autophagosome, for their presentation on a major histocompatibility complex (MHC) class II molecule are disclosed as are methods of use thereof for stimulating or enhancing immune responses in a subject. | 2010-10-21 |
| 20100266542 | RECEPTOR COUPLING AGENTS AND THERAPEUTIC USES THEREOF - Receptor coupling agents, including multivalent constructs comprising anti-TNF receptor binding moieties, for treating cancer and inhibiting tumor volume in a subject are disclosed. | 2010-10-21 |
| 20100266543 | LINKED DIBENZIMIDAZOLE ANTIVIRALS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 2010-10-21 |
| 20100266544 | NON-TOXIC CROSSLINKING REAGENTS TO RESIST CURVE PROGRESSION IN SCOLIOSIS AND INCREASE DISC PERMEABILITY - A method of improving the resistance of collagenous tissue to mechanical degradation in accordance with the present invention comprises the step of contacting at least a portion of a collagenous tissue with an effective amount of a crosslinking reagent. Methods and devices for enhancing the body's own efforts to stabilize discs in scoliotic spines by increasing collagen crosslinks. This stability enhancement is caused by reducing the bending hysteresis and increasing the bending stiffness of scoliotic spines, by injecting non-toxic crosslinking reagents into the convex side of discs involved in the scoliotic curve. Alternatively, contact between the tissue and the crosslinking reagent is effected by placement of a time-release delivery system directly into or onto the target tissue. Methods and devices that use crosslinking agents for increasing the permeability of an intervertebral disc, improving fluid flux to the intervertebral disc, and increasing the biological viability of cells within the intervertebral disc are provided. | 2010-10-21 |
| 20100266545 | OBLIGATELY ANAEROBIC MUTANT LACTIC ACID BACTERIUM AND PREPARATION METHOD THEREFOR, AND EXPRESSION VECTOR FUNCTIONING IN OBLIGATELY ANAEROBIC LACTIC ACID BACTERIUM - The present invention provides an obligately anaerobic lactic acid bacterium having no risk of causing side effects in normal tissue and promising as a safe therapeutic agent and a gene transporter for a disease that is in an anaerobic environment such as a solid tumor, a preparation method therefor, and an expression vector useful in the preparation method. The obligately anaerobic lactic acid bacterium of the present invention has been artificially mutated from being facultatively anaerobic to being obligately anaerobic and, furthermore, is capable of being transformed by an expression vector having introduced thereinto a gene for expressing an active protein useful for the treatment of a disease that is in an anaerobic environment. Furthermore, the expression vector of the present invention functions in an obligately anaerobic lactic acid bacterium and contains a | 2010-10-21 |
| 20100266546 | SELECTIVELY REPLICATING VIRAL VECTORS - The present invention provides recombinant viruses which replicate the viral genome selectively in response to the intracellular conditions of the target cell through the use a pathway-responsive promoter which substantially inhibits viral replication in the host cell based on the phenotypic or genotypic of the infected cell. In the target cell, the promoter element of the pathway-responsive promoter is inactive and thus the virus is permitted to replicate. This results in: (1) killing the cells by natural lytic nature of the virus, and/or (2) provides a therapeutic dose of a transgene product (amplified in comparison to replication incompetent vectors) to the target cell, and (3) producing a localized concentration of the virus facilitating the infection of surrounding cells to the recombinant virus. The invention further provides therapeutic and diagnostic methods of use of the vectors, pharmaceutical formulations comprising the vectors, methods of making the vectors and transformed cells comprising the vectors. | 2010-10-21 |
| 20100266547 | METHODS AND COMPOSITIONS FOR TREATMENT OF INTERFERON-RESISTANT TUMORS - The present invention provides a method for the treatment of interferon resistant tumors through the use of recombinant vectors encoding interferon species. In particular it is noted that interferon species provided by recombinant vectors possesses properties not associated with the recombinantly produced interferon proteins. The present invention further provides compositions useful in the treatment of interferon resistant tumors using recombinant vectors encoding interferons. | 2010-10-21 |
| 20100266548 | LPS-Responsive CHS1/Beige-Like Anchor Gene and Therapeutic Applications Thereof - The present invention relates to a novel LPS-responsive and Beige-like Anchor gene (lrba), variants of the lrba gene, fragments of the lrba gene, and polypeptides encoded thereby. The subject invention also pertains to lrba interfering RNA, and uses thereof. In another aspect, the present invention also includes methods of inhibiting tumor growth in a patient by suppressing lrba function. | 2010-10-21 |
| 20100266549 | NOVEL PROBIOTICS FOR PET FOOD APPLICATIONS - The present invention relates to novel lactic acid bacterial micro-organisms that have been isolated and selected for their probiotic potential and their use for the preparation of petfood compositions intended to improve the health of pets, and to compositions containing the same. | 2010-10-21 |
| 20100266550 | MAMMALIAN MILK MICROORGANISMS, COMPOSITIONS CONTAINING THEM AND THEIR USE FOR THE TREATMENT OF MASTITIS - The present invention relates to a novel approach to prevent or treat mastitis both in humans and animals through the use of mammal milk-derived microorganisms obtained from healthy hosts of the homologous species; to those new probiotic microorganisms obtained from milk able to reduce infectious mastitis and the method of screening used for their obtaining; to the use of these probiotic bacteria for the prophylaxis or treatment against mastitis and other diseases; and finally, to compositions comprising these compounds. | 2010-10-21 |
| 20100266551 | ADENO-ASSOCIATED VIRAL VECTORS FOR THE EXPRESSION OF DYSFERLIN - The present invention relates to a composition comprising: a first adeno-associated viral (AAV) vector comprising: i) a 5′ITR (Inverted Terminal Repeat) sequence of AAV; ii) a portion of gene placed under the control of a promoter; iii) a sequence comprising a splice donor site; iv) a 3′ITR sequence of AAV; and/or a second adeno-associated viral (AAV) vector comprising; v) a 5′ITR (Inverted Terminal Repeat) sequence of AAV; vi) a sequence comprising a splice acceptor site; vii) a portion of gene; viii) a 3′ITR sequence of AAV. The combination of the portions of gene carried by the first and second AAV vectors comprises an open reading frame which encodes a functional dysferlin. In addition, the combination of the sequence comprising the splice donor site and the sequence comprising the splice acceptor site contains all the elements necessary for the splicing, advantageously derived from a natural intron of the dysferlin gene. | 2010-10-21 |
| 20100266552 | TREATMENT OF CHRONIC LUNG DISEASE - A method of cellular therapy for a lung disease or condition in a subject is disclosed, wherein the method involves the administration of multipotent epithelial stem cells derived from amnion tissue (AECs). In a particular application, the method is used for the treatment of lung diseases and conditions such as chronic lung diseases including chronic obstructive pulmonary disease (COPD), acute lung conditions such as acute respiratory distress syndrome (ARDS), and ventilator associated lung injury (VALI). | 2010-10-21 |
| 20100266553 | METHOD FOR ISOLATING AND CULTURING ADULT STEM CELLS DERIVED FROM HUMAN AMNIOTIC EPITHELIUM - The present invention relates to a method for isolating and culturing adult stem cells derived from human amniotic membrane in high yield, and more particularly to a method for obtaining a large amount of adult stem cells, the method comprising obtaining amniotic epithelial cells from human amniotic tissue in high yield by treatment with dithiothreitol (DTT) and a low concentration of trypsin and culturing the amniotic epithelial cells in a medium containing a Rho-associated kinase inhibitor. The human amniotic epithelial cell-derived stem cells are easily extracted compared to existing therapeutic stem cells such as umbilical cord blood stem cells and bone marrow stem cells, the yield and proliferation thereof are significantly increased by DTT treatment, the addition of the ROCK inhibitor or the replacement of medium. Thus, the method can be used to efficiently prepare adult stem cells. | 2010-10-21 |
| 20100266554 | METHODS AND COMPOSITION FOR TREATING NEURAL DEGENERATION - Disclosed herein are methods and compositions for the use of marrow adherent stem cells and their descendents; e.g., bone marrow-derived neural regenerating cells; in the treatment of various neurodegenerative disorders. In certain embodiments, bone marrow-derived neural regenerating cells transplanted to sites of neural degeneration stimulate growth and/or survival of host neurons. | 2010-10-21 |
| 20100266555 | MICRO RNAS AS MARKERS OF THE FUNCTIONAL STATE OF A DENDRITIC CELL - The present invention relates to the use of specified micro RNAs as markers of the functional state of a dendritic cell. In one aspect the invention relates to a method for producing a quality-controlled therapeutic composition comprising dendritic cells. In another aspect the invention relates to a method of in vitro screening of immunomodulatory compounds. | 2010-10-21 |
| 20100266556 | METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND - An expansion agent for hematopoietic stem cells and/or hematopoietic progenitor cells useful for improvement in the efficiency of gene transfer into hematopoietic stem cells for gene therapy useful for treatment of various hematopoietic disorders is provided. | 2010-10-21 |
| 20100266557 | NOVEL PEPTIDE-BASED SCAFFOLDS FOR CARTILAGE REGENERATION AND METHODS FOR THEIR USE - Disclosed herein are novel peptide amphiphile molecules and compositions composed of a peptide sequence that non-covalently binds the growth factor TGF-β1. Also disclosed are methods of using these peptide amphiphiles to create a gel scaffold in situ that enhances articular cartilage regeneration when used in combination with microfracture. Significant improvement in tissue quality and overall O'Driscoll histological scores were observed in rabbits with full thickness articular cartilage defects treated with the TGF-binding peptide amphiphile. The gel can further serve as a delivery vehicle for recombinant TGF-β1 protein growth factor. Scaffolds that localize and retain chondrogenic growth factors may synergistically enhance cartilage repair when combined with microfracture, by inducing bone marrow mesenchymal stem cells into chondrogenic differentiation. This invention represents a promising new biomimetic approach to enhance current techniques of articular cartilage regeneration in the clinical setting. | 2010-10-21 |
| 20100266558 | METHOD AND ASSAY FOR GLYCOSYLATION PATTERN DETECTION RELATED TO CELL STATE OF STEM CELLS - A method and assay for characterizing populations of stem cells according to their glycosylation pattern, particularly for distinguishing between stem cell populations, for example with regard to state of differentiation. | 2010-10-21 |
| 20100266559 | STABILIZED, STERILIZED COLLAGEN SCAFFOLDS WITH ACTIVE ADJUNCTS ATTACHED - Bioimplants and methods of making the bioimplants are provided. The bioimplants comprise biological tissues having conjugated thereto adjunct molecules. The biological tissues are sterilized with a chemical sterilizing agent, such as a water soluble carbodiimide. The processes of making the bioimplants include a process in which an adjunct molecule is conjugated to a biological tissue during the sterilization process. | 2010-10-21 |
| 20100266560 | AGENT STABILISATION PROCESS AND PRODUCT - The invention relates to a composition and method of manufacture including a substrate coated with a biopolymer and aqueous biological gel and subsequently coated with at least one desiccation agent. The resulting composition is dry to touch, has a low water activity and stabilises the biological material for storage over at least one month at ambient temperatures. | 2010-10-21 |
| 20100266561 | Recovery of Tissue Function Following Administration of B Cells to Injured Tissue - The present invention relates generally to systems and methods of enhancing recovery of function of injured tissue through administration of a composition comprising a relatively pure populations of B lymphocyte cells in a pharmaceutically acceptable carrier to the injured tissue. Kits are provided to aid in purification of B cells from heterogeneous mixtures of cells and administration of B cells to injured tissue. | 2010-10-21 |
| 20100266562 | SELECTIVE CYTOPHERESIS DEVICES AND RELATED METHODS THEREOF - The present invention relates to systems and devices to treat and/or prevent inflammatory conditions within a subject and to related methods. More particularly, the invention relates to systems, devices, and related methods that sequester leukocytes and/or platelets and then inhibit their inflammatory action. | 2010-10-21 |
| 20100266563 | SELECTIVE CYTOPHERESIS DEVICES AND RELATED METHODS THEREOF - The present invention relates to systems and devices to treat and/or prevent inflammatory conditions within a subject and to related methods. More particularly, the invention relates to systems, devices, and related methods that sequester leukocytes and/or platelets and then inhibit their inflammatory action. | 2010-10-21 |
| 20100266564 | Polyunsaturated Fatty Acid Synthase Nucleic Acid Molecules and Polypeptides, Compositions, and Methods of Making and Uses Thereof - The present invention is directed to isolated nucleic acid molecules and polypeptides of thraustochytrid polyunsaturated fatty acid (PUFA) synthases involved in the production of PUFAs, including PUFAs enriched in docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), or a combination thereof. The present invention is directed to vectors and host cells comprising the nucleic acid molecules, polypeptides encoded by the nucleic acid molecules, compositions comprising the nucleic acid molecules or polypeptides, and methods of making and uses thereof. | 2010-10-21 |
| 20100266565 | Combinational Chemotherapy Treatment - Methods of combination chemotherapy that are effective for treating neoplasia are provided. | 2010-10-21 |
| 20100266566 | TREATMENTS INVOLVING GLUTAREDOXINS AND SIMILAR AGENTS - The present invention generally relates to treatments involving glutaredoxins. In one aspect, systems and methods of the invention can be used to treat a subject having an oxidative stress condition, for example, airway inflammation or asthma. In some embodiments, a glutaredoxin may be used to treat a subject. Also provided in certain aspects of the present invention are kits for therapies involving glutaredoxins, methods for promoting such therapies, and the like. | 2010-10-21 |
| 20100266567 | USE OF URATE OXIDASE FOR THE TREATMENT OR PROPHYLAXIS OF DISORDERS OR INDIRECT SEQUELAE OF THE HEART CAUSED BY ISCHEMIC OR REPERFUSION EVENTS - The invention relates to the use of a urate oxidase, preferably recombinant urate oxidase, for example rasburicase, for the treatment or prophylaxis of disorders or indirect sequelae of the heart caused by ischemic or reperfusion events, for example during and after cardiac surgery like CABG (coronary artery bypass graft), PCI (percutaneous coronary intervention), transplantation, post myocardial infarction and for the treatment or prophylaxis of coronary artery disease or heart failure, for example congestive heart failure. | 2010-10-21 |
| 20100266568 | EC SOD AND USE THEREOF - The present invention relates to an EC SOD and the use thereof. More particularly, the present invention relates to an EC SOD and the use thereof for preventing or treating skin diseases, particularly dermatitis or psoriasis. | 2010-10-21 |
| 20100266569 | PROSTATIC ACID PHOSPHATASE FOR THE TREATMENT OF PAIN - Methods and compositions are provided for the treatment of pain and cystic fibrosis. The methods include administering to an animal a composition or a pharmaceutical formulation comprising a therapeutically effective amount of a Prostatic Acid Phosphatase (“PAP”) polypeptide, or an active variant, fragment or derivative thereof, or a therapeutically effective amount of an activity enhancing PAP modulator. PAP is provided as a treatment for chronic pain including neuropathic and inflammatory pain in animals and humans. The PAP, or the active variant, fragment or derivative thereof, or the activity enhancing modulator of the PAP is administered via one or more of injection, intrathecal injection, oral administration, a surgically implanted pump, stem cells, viral gene therapy, or naked DNA gene therapy. Intrathecal injection of PAP functions as an analgesic and reduces thermal sensitivity in mice. PAP can reduce chronic mechanical and thermal inflammatory pain in mice. Allodynia and hyperalgesia due to nerve injury can be prevented by increasing PAP activity in spinal cord. | 2010-10-21 |
| 20100266570 | DIMERIC DERIVATIVES OF ARTEMISININ AND APPLICATION IN ANTICANCER THERAPY - The present invention relates to dimeric derivatives of 10-trifluoromethylated artemisinin of formula (I): or a pharmaceutically acceptable salt thereof with B | 2010-10-21 |
| 20100266571 | DOSING REGIMENS FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES USING PHARMACOLOGICAL CHAPERONES - The present invention provides dosing regimens for administering pharmacological chaperones to a subject in need thereof. The dosing regimens can be used to treat disorders caused by improper protein misfolding, such as lysosomal storage disorders. | 2010-10-21 |
| 20100266572 | TREATMENT AND PREVENTION OF ISCHEMIC INJURY USING ACTIVATED PROTEIN C - Methods and compositions are provided for treating or preventing ischemic injury in a tissue flap in order to reduce the incidence of flap necrosis. Some compositions comprise one or more of an activated protein C (APC), a functional fragment of an APC, an APC mimetic compound, and a derivative of APC. Some methods comprise administering to a subject a therapeutically effective amount of an agent comprising one or more of an activated protein C (APC), a functional fragment of an APC, an APC mimetic compound, and a derivative of APC. | 2010-10-21 |
| 20100266573 | METHOD AND MEANS FOR OBTAINING BRONCHORELAXATION - A method for producing bronchorelaxation in a human or an animal affected by airway obstruction comprises administration of a pharmacologically effective amount of elemental iodine on activated charcoal (iodinated activated charcoal) to the intestine of said human or animal. A pharmaceutical composition comprising elemental iodine on activated charcoal and uses thereof is also disclosed. | 2010-10-21 |
| 20100266574 | Oligoribonucleotides and Methods of Use Thereof for Treatment of Fibrotic Conditions and Other Diseases - The invention relates to a double-stranded compound, preferably an oligoribonucleotide, which down-regulates the expression of a gene of the TGase family at post-transcriptional level. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide, and a pharmaceutically acceptable carrier. The present invention also contemplates a method of treating a patient suffering from fibrotic disease such as kidney and liver fibrosis and ocular scarring comprising administering to the patient the pharmaceutical composition in a therapeutically effective amount so as to thereby treat the patient. The invention also relates to treatment of fibrotic and other diseases by use of antibodies to TGase polypeptides. | 2010-10-21 |
| 20100266575 | SOLUBLE FMS-LIKE TYROSINE KINASE-1 (sFLT-1) ANTIBODY AND RELATED COMPOSITION, KIT, METHODS OF USING, AND MATERIALS AND METHOD FOR MAKING - An isolated antibody that specifically binds to sFlt-1 or a fragment thereof having (i) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO: 2, (ii) a variable light domain region comprising the amino acid sequence of SEQ ID NO: 4, or (iii) both (i) and (ii), a pharmaceutical composition and a kit comprising such an antibody, a method of making such an antibody, a method of determining the presence, amount or concentration of sFlt-1 or a fragment thereof in a test sample, a method of treating a patient in therapeutic or prophylactic need of an antagonist of sFlt-1, an isolated nucleic acid comprising a nucleotide sequence encoding the amino acid sequence of (i) SEQ ID NO: 2, (ii) SEQ ID NO: 4, or (iii) both (i) and (ii), optionally as part of a vector, and a host cell comprising and expressing such a nucleic acid. | 2010-10-21 |
| 20100266576 | USE OF A CAMELID SINGLE-DOMAIN ANTIBODY FOR DETECTING AN OLIGOMERIC FORM OF AN AMYLOID BETA PEPTIDE AND ITS APPLICATIONS - Use of camelid single-domain antibodies for detecting an oligomeric form of the amyloid β peptide 42 and their therapeutic and diagnostic applications. | 2010-10-21 |
| 20100266577 | Method of Cancer Treatment with Antagonists of FAS Inhibitors - In one embodiment, the present invention relates to a method of treating a cancer characterized by inhibition of Fas-mediated apoptosis, comprising administering to a patient suffering from the cancer a pharmaceutically-effective amount of a composition comprising a peptide that competitively antagonizes at least one protein-Fas binding selected from the group consisting of herpes virus 8 protein K1 binding to Fas, CD74 binding to Fas, and pi 00 binding to Fas. In a further embodiment, the peptide is selected from the group consisting of peptides having from about 15 to about 35 amino acid residues and comprising at least a portion of the immunoglobulin domain of K1, peptides having from about 15 to about 35 amino acid residues and comprising at least fifteen consecutive amino acid residues among positions 50-120 of CD74, LVTLLLAGQ ATT A YFL YQQQ, LYQQQGRLDKLTVTSQNLQL, QNLQLENLRMKLPKPPKPVS, and PKPVSKMRMATPLLMQALPM. In another embodiment, the present invention relates to a method of treating a disease characterized by unwanted apoptosis in a mammal, comprising transfecting a cell of the mammal with a nucleic acid molecule encoding CD74. The present invention also relates to the compositions referred to above and their use in manufacture of medicaments for treatment of the diseases described herein. | 2010-10-21 |
| 20100266578 | TREATMENT AND DIAGNOSTIC METHODS FOR HYPERSENSITIVE DISORDERS - The current standard of care for the treatment of allergic airway diseases include short and long acting beta-agonists, and inhaled or systemic corticosteroids, cromolyn and xanthines that all have the potential of detrimental side-effects. The present invention describes a new mechanistic protein-based therapeutic approach for the treatment of allergic airway disease and diseases associated with excessive Th2 pathology. The present invention relates to the surprising discovery that serum amyloid P (SAP) demonstrates a therapeutic affect in the treatment of hypersensitive disorders. | 2010-10-21 |
| 20100266579 | TREATMENT OF INFLAMMATORY DISEASES - We describe the involvement of JunD in the activation of macrophages and the association of JunD in inflammatory diseases and conditions. | 2010-10-21 |
| 20100266580 | TRANSLOCATION AND MUTANT TNK1 KINASE IN HUMAN LYMPHOMA - In accordance with the invention, a novel gene translocation in human Hodgkin's lymphoma (HL) that results in a fusion protein combining part of C17ORF61 with Thirty-eight-negative kinase 1 (Tnk1) kinase has now been identified. The TNK1-C17ORF61 fusion protein, which retains TNK1 tyrosine kinase activity, was confirmed to drive the proliferation and survival of Hodgkin's lymphoma (HL) cell line, L-540. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant TNK1 kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The disclosed identification of this new fusion protein and truncated kinase enables new methods for determining the presence of these mutant TNK1 kinase polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides, which are also provided by the invention. | 2010-10-21 |
| 20100266581 | COMPOSITIONS AND METHODS FOR MODULATING S-NITROSOGLUTHIONE REDUCTASE - Disclosed herein are methods and compositions for modulating the levels and/or activity of S-nitrosoglutathione reductase (GSNOR) in vivo or in vitro. Specifically disclosed are GSNOR deletion constructs, host cells and non-human mammals comprising GSNOR deletions, and methods of screening employing GSNOR deletion mutants. Also specifically disclosed are reagents and procedures for measuring, monitoring, or altering GSNOR levels or activity (as well as nitric oxide and S-nitrosothiol levels) in connection with various medical conditions. | 2010-10-21 |
| 20100266582 | INHIBITION OF IL-17 PRODUCTION - The invention concerns inhibition of the production of proinflammatory cytokine interleukin-17 (IL-17) by T cells, using an antagonist of interleukin-23 (IL-23). The invention further concerns the use of IL-23 antagonists in the treatment of inflammatory diseases characterized by the presence of elevated levels of IL-17. IL-23 antagonists include, without limitation, antibodies specifically binding to a subunit or IL-17 or an IL-17 receptor. The invention additionally concerns induction of IL-7 production by using an IL-23 agonist. | 2010-10-21 |
| 20100266583 | INHIBITION OF IL-17 PRODUCTION - The invention concerns inhibition of the production of proinflammatory cytokine interleukin-17 (IL-17) by T cells, using an antagonist of interleukin-23 (IL-23). The invention further concerns the use of IL-23 antagonists in the treatment of inflammatory diseases characterized by the presence of elevated levels of IL-17. IL-23 antagonists include, without limitation, antibodies specifically binding to a subunit or IL-17 or an IL-17 receptor. The invention additionally concerns induction of IL-7 production by using an IL-23 agonist. | 2010-10-21 |
| 20100266584 | ANTIBODIES AGAINST THE ECTODOMAIN OF ERBB3 AND USES THEREOF - The present invention provides a novel class of antibodies and antigen binding fragments thereof that bind the extracellular domain of ErbB3 receptor and inhibit various ErbB3 functions. For example, the antibodies and antigen binding fragments described herein are capable of binding to the receptor designated ErbB3 and inhibiting EGF-like ligand mediated phosphorylation of the receptor. Such antibodies and antigen binding fragments thereof have the useful characteristic of inhibiting the proliferation of cancer cells expressing ErbB3. | 2010-10-21 |
| 20100266585 | Monoclonal Antibodies Specific to Hemagglutinin and Neuraminidase from Influenza Virus H5-Subtype or N1-Subtype and Uses Thereof - Monoclonal antibodies and related binding proteins that bind specifically to the envelope glycoprotein of H5 subtypes or neuraminidase glycoprotein of N1 subtypes of avian influenza virus (AIV) are provided. The monoclonal antibodies and related binding proteins are useful for the detection of H5 and N1 subtypes of AIV, including H5N1 subtypes and provide means for the diagnosis, surveillance and treatment of dangerous viral infections. | 2010-10-21 |
| 20100266586 | VARIABLE ANTIBODIES - The present invention discloses inhibitory antibodies against Factor VIII with modified glycosylation, either by enzymatic deglycosylation or by site directed mutagenesis. Said antibodies with modified glycosylation have equal affinity for FVIII but show different inhibiting properties. The use of one or a mixture of said antibodies allow modulation of the inhibition of factor VIII to levels between 40 and 95%. The present invention further discloses pharmaceutical compositions comprising inhibitory antibodies against Factor VIII with modified glycosylation, combinations of these antibodies and methods for treating haemostasis disorders using said antibodies and antibody mixtures. | 2010-10-21 |
| 20100266587 | Compositions and Methods to Treat Acute Myelogenous Leukemia - Compositions and methods for treating or preventing a hematologic malignancy, such as AML, using an anti-alpha4 antibody are described. | 2010-10-21 |
| 20100266588 | Breast Cancer Susceptibility Gene GT198 and Uses Thereof - It has been discovered that the human GT198 gene (gene symbol PSMC3IP) at chromosome 17q21 acts as a tumor suppressor. The mutation of the GT198 gene causes the increased dominant negative splice variant activity and leads to the loss of wild type GT198 function, and in turn, induces breast and ovarian cancers. One embodiment provides compositions and methods for treating or alleviating one or more symptoms associated with cancer due to the GT198 gene mutations. Another embodiment provides methods and compositions for detecting cancer due to the mutation of the GT198 gene. Still another embodiment provides methods for identifying compounds, antibodies and natural product molecules that are useful for treating cancer due to the mutations of the GT198 gene. Preferably the disclosed compositions antagonize or interfere with the biological activity of splice variants of GT198. | 2010-10-21 |
| 20100266589 | ADJUVANT CANCER THERAPY - Disclosed herein are methods and compostions comprising anti-VEGF antibodies for use in adjuvant cancer therapy. | 2010-10-21 |
| 20100266590 | COMBINATION THERAPY - Disclosed are methods for treating various cancers. Methods encompass the administration of a first drug such as AP23573, temsirolimus or everolimus in combination with a second drug selected from Remicade, Humira, Enbrel, Raptiva, Abatacept, Actermra, Cimzia or anakinra. | 2010-10-21 |
| 20100266591 | METHOD OF TREATING ERYTHROPOIETIN HYPORESPONSIVE ANEMIAS - The invention relates to methods of using compositions comprising EPO-mimetic peptides to treat anemia. The invention relates to methods of treating disorders characterized by the insufficient amounts of erythrocytes and hemoglobulin in the blood due to myelodysplastic syndrome (MDS) or by hemoglobinopathies, such as alpha- or beta-thalessemia or sickle cell disease. | 2010-10-21 |
| 20100266592 | THERAPEUTIC ANTENNAPEDIA-ANTIBODY MOLECULES AND METHODS OF USE THEREOF - The present invention is based on the seminal discovery that an antibody or fragment thereof combined with Antennapedia or a fragment thereof, is an effective therapeutic agent. The invention describes the construction of antibody or antibody fragment fused or chemically conjugated with Antennapedia at its carboxyl or its amino terminus (a “cargo-carrier” construct). | 2010-10-21 |
| 20100266593 | WNT ANTAGONISTS AND THEIR USE IN THE DIAGNOSIS AND TREATMENT OF WNT-MEDIATED DISORDERS - The present invention provides for chimeric Wnt antagonists comprising a Frz domain component derived from a Frizzled protein, a secreted Frizzled related protein or Ror protein and an Fc immunoglobulin component, and their use in the treatment and diagnostic detection of cellular Wnt signaling and Wnt-mediated disorders, including cancer. | 2010-10-21 |
| 20100266594 | IL-9 IN FIBROTIC AND INFLAMMATORY DISEASE - The present invention encompasses methods of employing inhibitors of IL-9 in the treatment of fibrotic disorders, e.g., COPD and inflammatory bowel disease. | 2010-10-21 |
| 20100266595 | TREATMENT OF INSULIN-RESISTANT DISORDERS - The invention concerns the treatment of insulin-resistant disorders. In particular, the invention concerns the treatment of insulin-resistant disorders by administration of IL-17, such as IL-17A and/or IL-17F antagonists, such as anti-IL-17A and/or IL-17F and/or IL-17Rc antibodies, or antibody fragments. | 2010-10-21 |
| 20100266596 | THERAPEUTIC ANTIBODY PURIFICATION METHOD AND METHOD OF USE - A method of preparing anti-b amyloid immunoglobulin involves treating human plasma anti-b amyloid immunoglobulin under alkaline conditions, such as at pH 10.25 to 11.75 using diethylamine HCl, to dissociate b amyloid protein therefrom. Typically, the anti-b amyloid immunoglobulin is present in human immunoglobulin preparations obtained from plasma or serum. Anti-b amyloid immunoglobulin prepared by the method is substantially free of b amyloid protein and has therapeutic activity in compositions and/or methods for treating a disease or condition associated with b amyloid plaques, such as Alzheimer's disease. | 2010-10-21 |
| 20100266597 | CYTOKINE RECEPTOR ZCYTOR17 MULTIMERS - Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto. | 2010-10-21 |
| 20100266598 | PEPTIDE THAT ELICITS NEUTRALIZING ANTIBODIES TARGETING THE HIV CO-RECEPTOR, CCR5 - The present invention relates, e.g., to an isolated peptide comprising a sequence of contiguous amino acids that is at least about 60% identical (e.g., at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 100% identical) to the sequence E-W-Q-K-E-G-L-V-T-L-W-L (SEQ ID NO:1), or an active variant of an isolated peptide comprising SEQ ID NO:1. Neutralizing antibodies generated by, or specific for, such peptides are also described, in particular antibodies which are specific for the HIV co-receptor, CCR5, and which inhibit infection of a host cell by HIV. Neutralizing single strand and complete human monoclonal antibodies against CCR5 are described. Methods of using such peptides or antibodies, for inhibiting infection by HIV, are also described. | 2010-10-21 |
| 20100266599 | HUMAN RECEPTOR PROTEINS; RELATED REAGENTS AND METHODS - Nucleic acids encoding mammalian Toll-like receptors (TLRs) have been identified in human cells. Recombinantly produced TLRs are used in the preparation of antibodies that are capable of binding to the TLRs. The antibodies are advantageously used in the prevention and treatment of septic shock, inflammatory conditions, and viral infections. | 2010-10-21 |
